title: Hepatitis C virus infection and rituximab therapy after renal transplantation.
abstract: BACKGROUND
  Rituximab, a chimeric monoclonal antibody, has been successfully given in various diseases including HCV-associated mixed cryoglobulinemia. However, only preliminary data exists on its efficacy and safety after renal transplantation.
  
  
  METHODS
  We report on a renal transplant recipient with chronic hepatitis C who received rituximab therapy for gastric cancer. Four rituximab infusions of 375 mg/m(2) were given.
  
  
  RESULTS
  Rituximab therapy was complicated by cholestatic hepatitis C with very high HCV RNA levels; liver insufficiency occurred. The patient developed bacterial pneumoniae and respiratory insufficiency was the cause of death. Although other mechanisms cannot be excluded, we found that rituximab therapy was implicated in the pathogenesis of cholestatic hepatitis C in our patient.
  
  
  CONCLUSIONS
  We suggest that rituximab therapy may be associated with significant side effects. More experience has to be accumulated before any conclusions on efficacy and safety of rituximab therapy after RT can be drawn.
authors.affiliation: Division of Nephrology and Dialysis, Maggiore Hospital, IRCCS, Milan, Italy. fabrizi@policlinico.mi.it
authors.forename: F
authors.initials: F
authors.lastname: Fabrizi
authors.forename: P
authors.initials: P
authors.lastname: Martin
authors.forename: A
authors.initials: A
authors.lastname: Elli
authors.forename: G
authors.initials: G
authors.lastname: Montagnino
authors.forename: G
authors.initials: G
authors.lastname: Banfi
authors.forename: P
authors.initials: P
authors.lastname: Passerini
authors.forename: M R
authors.initials: MR
authors.lastname: Campise
authors.forename: A
authors.initials: A
authors.lastname: Tarantino
authors.forename: C
authors.initials: C
authors.lastname: Ponticelli
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000473:pathology* / Q000821:virology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy; D012367:RNA, Viral; D000069283:Rituximab; D013274:Stomach Neoplasms / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D012367:RNA, Viral; D000069283:Rituximab